Analyst Price Targets — PCRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 8, 2025 9:27 pm | — | Barclays | $27.00 | $24.42 | TheFly | Pacira initiated with an Equal Weight at Barclays |
| February 28, 2025 6:37 pm | — | Barclays | $24.00 | $24.05 | TheFly | Pacira price target raised to $24 from $17 at Barclays |
| February 28, 2025 11:11 am | — | H.C. Wainwright | $48.00 | $24.05 | TheFly | Pacira price target raised to $48 from $39 at H.C. Wainwright |
| January 30, 2025 11:03 am | Les Sulewski | Truist Financial | $25.00 | $26.03 | StreetInsider | Truist Securities Upgrades Pacira Pharmaceuticals (PCRX) to Buy |
| November 7, 2024 12:42 pm | David Amsellem | Piper Sandler | $12.00 | $17.37 | StreetInsider | Pacira Pharmaceuticals (PCRX) PT Raised to $12 at Piper Sandler |
| September 24, 2024 9:32 am | Glen Santangelo | Jefferies | $18.00 | $14.77 | StreetInsider | Pacira Pharmaceuticals (PCRX) PT Raised to $18 at Jefferies |
| August 13, 2024 6:08 am | Les Sulewski | Truist Financial | $8.00 | $12.29 | TheFly | Pacira downgraded to Sell from Buy at Truist |
| July 2, 2024 12:36 pm | Oren Livnat | H.C. Wainwright | $57.00 | $21.91 | TheFly | Pacira should be bought on today's selloff, says H.C. Wainwright |
| June 13, 2024 11:57 am | Glen Santangelo | Jefferies | $36.00 | $28.50 | StreetInsider | Jefferies Reiterates Buy Rating on Pacira Pharmaceuticals (PCRX) |
| May 21, 2024 8:52 am | David Amsellem | Piper Sandler | $42.00 | $30.68 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Pacira Pharmaceuticals (PCRX) |
Latest News for PCRX
Shares of Pacira BioSciences, Inc. (NASDAQ: PCRX - Get Free Report) gapped down prior to trading on Friday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $22.59, but opened at $21.14. Pacira BioSciences shares last traded at $21.8740, with a volume of 657,370 shares traded. The company reported $0.57
PCRX misses Q4 earnings and revenue estimates as expenses surge and shares slide, despite Exparel growth and a new 2026 outlook.
While the top- and bottom-line numbers for Pacira (PCRX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Pacira BioSciences, Inc. (PCRX) Q4 2025 Earnings Call Transcript
Pacira (PCRX) came out with quarterly earnings of $0.57 per share, missing the Zacks Consensus Estimate of $0.85 per share. This compares to earnings of $0.91 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PCRX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.